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Abstract
Heart failure (HF) is a major epidemic with rising morbidity and mortality rates that encumber global healthcare systems. While
some studies have demonstrated the value of CRP in predicting (i) the development of HFpEF and (ii) long-term clinical
outcomes in HFpEF patients, others have shown no such correlation. As a result, we conducted the following systematic review
and meta-analysis to assess both the diagnostic and prognostic role of CRP in HFpEF. PubMed and Embase were searched for
studies that assess the relationship between CRP and HFpEF using the following search terms: (((C-reactive protein) AND
((preserved ejection fraction) OR (diastolic heart failure))). The search period was from the start of database to August 6, 2019,
with no language restrictions. A total of 312 and 233 studies were obtained from PubMed and Embase respectively, from which
19 studies were included. Our meta-analysis demonstrated the value of a high CRP in predicting the development of not only new
onset HFpEF (HR: 1.08; 95% CI: 1.00–1.16; P = 0.04; I2 = 22%), but also an increased risk of cardiovascular mortality when
used as a categorical (HR: 2.52; 95% CI: 1.61–3.96; P < 0.0001; I2 = 19%) or a continuous variable (HR: 1.24; 95% CI: 1.04–
1.47; P = 0.01; I2 = 28%), as well as all-cause mortality when used as a categorical (HR: 1.78; 95% CI: 1.53–2.06; P < 0.00001;
I2 = 0%) or a continuous variable: (HR: 1.06; 95% CI: 1.02–1.06; P = 0.003; I2 = 61%) in HFpEF patients. CRP can be used as a
biomarker to predict the development of HFpEF and long-term clinical outcomes in HFpEF patients, in turn justifying its use as a
simple, accessible parameter to guide clinical management in this patient population. However, more prospective studies are still
required to not only explore the utility and dynamicity of CRP in HFpEF but also to determine whether risk stratification
algorithms incorporating CRP actually provide a material benefit in improving patient prognosis.
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Introduction
Heart failure (HF) is a major epidemic with rising morbidity
and mortality rates that encumber global healthcare systems.
The 2016 European Society of Cardiology Guidelines denotes
three classes of HF, stratified primarily according to ejection
fraction: (i) HF with reduced ejection fraction (HFrEF),
wherein EF in less than 40%; (ii) HF with midrange ejection
fraction (HFmrEF), wherein EF is between 40 and 50%; (iii)
HF with preserved ejection fraction (HFpEF), wherein EF is
greater than 50% [1]. Although an abundance of evidence
exists detailing the epidemiology, pathophysiology, and opti-
mal treatment strategies for HFrEF, there much unknown
pertaining to its counterpart, HFpEF.
The pathogenesis of both HFrEF and HFpEF differ, and as
such, therapies proven to be effective for HFrEF have often
failed to yield the same favorable outcomes in HFpEF cohorts.
One of the suggested mechanisms contributing to the devel-
opment of HFpEF is a systemic inflammatory state that ad-
versely affects cardiomyocyte function on a molecular level.
This inflammatory milieu is characterized by an elevation in
the serum levels of various biomarkers [2], one of which is C-
reactive protein (CRP): an acute phase protein produced by
hepatocytes in a reactive response to inflammation [3].
Many investigations have analyzed the use of CRP as a
biomarker to predict not only the development of HFpEF
but also long-term clinical outcomes that may occur in
HFpEF patients. However, while some studies have demon-
strated a relationship between CRP and HFpEF, others have
shown no such correlation. As a result, we conducted the
following systematic review and meta-analysis to assess both
the diagnostic and prognostic role of CRP in HFpEF.
Methods
Search strategy, inclusion, and exclusion criteria
This systematic review and meta-analysis was performed ac-
cording to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [4].
PubMed and Embase were searched up to August 6, 2019,
with no language restrictions, for studies assessing the rela-
tionship between CRP and HFpEF development as well as
outcomes inHFpEF patients. The following search terms were
used: (C-reactive protein) AND ((preserved ejection fraction)
OR (diastolic heart failure)). The inclusion criteria was as
follows: (i) the study was a prospective or retrospective cohort
study in humans and (ii) hazard ratios for risk of new onset
HFpEF as well as prognostic outcomes including cardiovas-
cular (CV) mortality, long-term CV outcomes, and all-cause
mortality were reported in the published data.
The Newcastle–Ottawa Quality Assessment Scale (NOS)
was used for quality assessment of the included studies. The
NOS point score system evaluated the categories of study
participant selection, comparability of the results, and quality
of the outcomes. The following characteristics were assessed:
(a) representativeness of the exposed cohort, (b) selection of
the non-exposed cohort, (c) ascertainment of exposure, (d)
demonstration that outcome of interest was not present at the
start of study, (e) comparability of cohorts based on study
design or analysis, (f) assessment of outcomes; (g) follow-up
periods that were sufficiently long for outcomes to occur, and
(h) adequacy of follow-up of cohorts. This scale ranged from
zero to nine stars, which indicated that studies were graded as
poor quality if the score was < 5, fair if the score was 5 to 7,
and good if the score was > 8.
Data extraction and statistical analysis
Data from the different studies were entered in pre-designed
spreadsheets using Microsoft Excel. All abstracts were re-
trieved as complete manuscripts and assessed against the in-
clusion criteria. The data extracted include: (i) publication
details: last name of first author, publication year, and loca-
tions; (ii) study design; (iii) follow-up duration; (iv) end-
point(s); (v) quality score; and (vii) characteristics of the pop-
ulation including sample size, gender, age, and number of
subjects. Two reviewers (IL and KL) reviewed each included
study independently. Disagreements were resolved by adjudi-
cation with input from a third reviewer (GT).
S ta t i s t i ca l ana lys i s was per formed us ing the
Comprehensive Meta-Analysis Software (Version 3).
Heterogeneity between studies was determined using
Cochran’s Q value, the weighted sum of squared differences
between individual study effects and the pooled effect across
studies, and the I2 statistic determined from the standard chi-
square test, which describes the proportion of total variance-
explained heterogeneity. I2 > 50% was considered to reflect
significant statistical heterogeneity. A fixed effects model was
used if I2 < 50%; otherwise, the random effects model using
the inverse variance heterogeneity method was used. To iden-
tify the source of the heterogeneity, a sensitivity analysis using
the leave-one-out method was performed. Funnel plots, Begg
and Mazumdar rank correlation test, and Egger’s test were
also used to assess for possible publication bias.
Results
Figure 1 demonstrated the study identification and selection
process. Three hundred and twelve and 233 studies were ob-
tained from PubMed and Embase respectively, from which a
total of 19 studies satisfied the inclusion criteria. The details of
the NOS quality assessment for the included cohort studies are
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shown in Supplementary Table 1. Baseline characteristics of
these studies and of the study populations are shown in
Table 1. A total of 51,196 patients with a mean age of 61.1
± 13.9 years were included. Fifty percent of the population
was male, and the mean follow-up period was 120 months.
Diagnostic value of CRP in predicting new onset
HFpEF
Eight studies [5–9] examined the correlation between CRP as
a continuous variable and the risk of new onset HFpEF
(Fig. 2a). Among these, De Boer et al. examined the risk of
HFpEF development in four longitudinal cohorts (the
Framingham Heart Study (FHS); the Cardiovascular Health
Study (CHS); the Prevention of Renal and Vascular End-stage
Disease (PREVEND) cohort; the Multi-Ethnic Study of
Atherosclerosis (MESA)). Meta-analysis of the included stud-
ies using the independent associations reported in de Boer
et al. revealed a significant relationship between CRP and
HFpEF development (HR: 1.08; 95% CI: 1.01–1.16; P =
0.04; I2 = 22%). It should be noted that Brouwers et al. and
Silverman et al. also assessed this relationship using the
PREVEND and MESA cohorts, respectively, but did so using
a larger sample size. As a result, in order to avoid potentially
meta-analyzing overlapping populations a subset analysis was
performed, with the findings of Browuers et al. (PREVEND
Cohort) and Silverman et al. (MESA cohort) included and
those of the PREVEND and MESA patients in de Boer et al.
excluded (Fig. 2b). Subsequent meta-analysis in turn showed
that a high CRP was still significantly associated with a 9%
increase in the risk of new onset HFpEF, a result reported with
a lower heterogeneity than that of the aforementioned (HR:
1.09; 95% CI: 1.01–1.18; P = 0.04; I2 = 0%).
Prognostic value of CRP in predicting outcomes
following HFpEF
Cardiovascular mortality
Two studies [10, 11] examined the prognostic value of CRP as
a categorical variable in predicting CV mortality in HFpEF
patients (Fig. 3a). Subsequent meta-analysis revealed that a
high CRP significantly predicted a greater than twofold in-
crease in the risk of CV mortality (HR: 2.52; 95% CI: 1.61–
3.96; P < 0.0001; I2 = 19%). Furthermore, two additional
studies [10, 12] also assessed this relationship but instead
utilized CRP as a continuous variable (Fig. 3b). Of these
two, only one reported a significant relationship. Meta-
analysis of these studies indicated yet another significant, al-
beit smaller, association (HR: 1.24; 95% CI: 1.05–1.47; P =
0.01; I2 = 28%).
Cardiovascular outcomes
A total of three studies [13–15] assessed the relationship be-
tween CRP as a categorical variable and the risk of long-term
adverse CVoutcomes (Fig. 4a). Chen et al. used a composite
endpoint of CV death, myocardial infarction (MI), and unsta-
ble angina pectoris, while Vrsalović et al. and Sabatine et al.
employed composite outcomes of MACE and CV death, MI,
or stroke respectively. Two of these three studies were inde-
pendently significant, and subsequent meta-analysis showed
that a high CRP was in fact related to a greater risk of long-
term adverse cardiovascular outcomes (HR: 1.55; 95% CI:
1.22–1.96; P < 0.0003; I2 = 37%). Two studies [16, 17] exam-
ined such a relationship by using CRP as a continuous vari-
able (Fig. 4b). Both employed the same composite endpoint in
Fig. 1 Study identification and
selection process from PubMed
and Embase
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their investigations: CV death, MI, unstable angina pectoris,
non-ischemic stroke, hospitalization for HF decompensation,
and coronary revascularization. Meta-analysis of these stud-
ies, however, did not report a significant association (HR:
1.09; 95% CI: 0.88–1.34; P = 0.44; I2 = 83%).
All-cause mortality
Five studies [10, 11, 14, 18, 19] investigated the correlation
between CRP as a categorical variable and all-cause mortality
in HFpEF patients (Fig. 5a). Meta-analysis of these studies
showed that a high CRP predicted a 78% increase in the risk
of all-cause mortality (HR: 1.78; 95% CI: 1.53–2.06;
P < 0.00001; I2 = 0%). Likewise, similar findings were dem-
onstrated when employing CRP as a continuous variable
(Fig. 5b). A total of seven studies [10, 12, 19–23] assessed
this relationship, of which only four reported significant re-
sults. Subsequent meta-analysis of these studies, however, il-
lustrated yet again that a high CRP as a continuous variable
was significantly associated with an increased risk of all-cause
mortality (HR: 1.06; 95% CI: 1.02–1.10; P = 0.004; I2 =
61%).
Sensitivity and bias analyses
The results of sensitivity analysis performed by excluding one
study at a time are shown in Supplementary Figure 1A to H.
The results of publication bias are shown in Supplementary
Figures 2A to E.
Discussion
The findings of this systematic review and meta-analysis are
that CRP has both diagnostic value in predicting the risk of
new onset HFpEF, as well as prognostic value in predicting
cardiovascular outcomes and all-cause mortality following
HFpEF development.
HFrEF and HFpEF are binary oppositions on the same
disease spectrum. The mechanism of HFrEF is well under-
stood, and primarily involves an initial insult that triggers
myocardial injury as well as adverse remodeling, culminating
in a reduction of cardiac output [24]. However, HFpEF instead
represents a more complex syndrome comprised of a hetero-
geneous phenotype secondary to many different interacting
pathophysiological processes [25]. As aforementioned, the
Fig. 2 High CRP as a continuous
variable and risk of new onset
HFpEF: a without the exclusion
of overlapping cohorts; bwith the
exclusion of overlapping cohorts
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systemic pro-inflammatory hypothesis serves as a novel par-
adigm for the pathogenesis of HFpEF. Paulus et al. indicates
that this systemic inflammatory state is induced by multiple
underlying, synergistically acting comorbidities, many of
which were consistently present at baseline in most of the
HFpEF cohorts included in this meta-analysis, such as obesity,
Fig. 3 High CRP as a a
categorical variable and risk of
cardiovascular mortality; as a b
continuous variable and risk of
cardiovascular mortality
Fig. 4 High CRP as a a
categorical variable and risk of
cardiovascular outcomes; as a b
continuous variable and risk of
cardiovascular outcomes
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hypertension, diabetes mellitus (DM), and chronic obstructive
pulmonary disease (COPD) [26]. This inflammation is char-
acterized by a patterned elevation of cytokines and acute
phase reactants, which collectively mediate the production
of reactive oxygen species (ROS) from the coronary endothe-
lium, thereby leading to a decrease in nitric oxide-cyclic gua-
nosine monophosphate (NO-cGMP) signaling in the adjacent
myocardium. It should be noted that CRP not only contributes
to a reduction in coronary endothelial NO bioavailability by
this mechanism but also likely through its direct downregula-
tion of endothelial nitric oxide synthase [27]. All in all, im-
pairment of the NO-cGMP pathway in turn leads to collagen
deposition, left ventricular remodeling, and subsequent dia-
stolic dysfunction [26].
Although there is paucity in literature discussing the role of
CRP in HFpEF, CRP has long known to be correlated with a
higher incidence of cardiac events in patients with existing
cardiovascular disease (CVD). CRP can be synthesized by
both hepatic and extrahepatic tissues with the rate of its pro-
duction conditioned on the severity of the underlying patho-
logical condition [28], making it a sensitive marker for risk
assessment [29]. Nonetheless, despite the demonstrated pre-
dictive value of baseline CRP in CVD [30, 31], problems exist
with its use primarily due to its lack of specificity.
Furthermore, currently in clinical practice, serum CRP con-
centrations are traditionally categorized into three tertiles: (i)
< 1 mg/l, (ii) 1–3 mg/l, and (iii) > 3 mg/l, wherein tertile two
and tertile three are associated with a 50% and 100% greater
cardiovascular risk than tertile one, respectively [32].
However, in an observational study showcasing the effect of
population characteristics on CRP,Werner et al. illustrates that
age, sex, and ethnicity can all impact serum CRP concentra-
tions. This influence of patient demographics potentially ac-
counts for the various, distinct CRP cutoffs present in the
studies included in this meta-analysis, and in turn lends cre-
dence to the notion that cutoffs adjusted for baseline factors
are needed in order to achieve adequate risk stratification in
the clinical setting [33].
Limitations
There are several limitations for this systematic review and
meta-analysis that should be noted. Firstly, this is a study-
level meta-analysis in contrast to a data-level meta-analysis,
which could improve the accuracy of our findings. Secondly,
significant heterogeneity (I2 > 50) was observed with certain
Fig. 5 High CRP as a a
categorical variable and risk of
all-cause mortality; as a b contin-
uous variable and risk of all-cause
mortality
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effect sizes. This may be due to the differences in the charac-
teristics of the study populations, study design, CRP cutoff
values or intervals, blood sampling time, and CRP measure-
ment method (as serum hsCRP or CRP). Thirdly, as a marker
for systemic inflammation, it is clearly evident that serum
CRP concentrations can be affected by many diseases other
than HFpEF that also predispose to a pro-inflammatory state.
Some studies consisted of patients withHFpEF that developed
as sequelae to such underlying inflammatory conditions in-
cluding but not limited to coronary artery disease, peripheral
vascular disease, end-stage renal disease, and hypertensive
heart disease. In these cases, it is difficult to determine whether
the elevation of CRP in these subjects is due to the indepen-
dent effect of the disease itself, the HFpEF phenotype, or most
likely, a combination of both. As such, the presence of co-
existing diseases may have not only skewed the overall effect
sizes but also, in light of its aforementioned lack of specificity,
CRP will likely only be useful as an accessorial form of guid-
ance in the clinical management of HFpEF patients, as op-
posed to a forerunning parameter used as the basis of risk
stratification. Fourthly, it must be noted that there is likely
an association between CRP and the severity of HFpEF be-
cause, as aforementioned, the degree of elevation in serum
CRP concentration is related to the extent of the underlying
inflammatory condition. As a result, the relationship between
CRP and clinical outcomes may simply reflect a relationship
between HFpEF severity and clinical outcomes. If CRP is
merely a surrogate for HFpEF severity, then it is likely that
CRP is a marker, rather than a predictor, for outcomes in
HFpEF.
Conclusions
The findings of this systematic review and meta-analysis in-
dicate that CRP could be used as a biomarker that not only
predicts the development of new onset HFpEF but also clini-
cal outcomes following HFpEF in the long run. However, it
should be noted that the present study possesses all the tradi-
tional limitations that typically accompanymeta-analyses, and
as such, readers should consider the fact that the reported
diagnostic and prognostic potential of CRP in HFpEF is only
accurate if said limitations are of no relevance. As a result,
given the inherent methodological restrictions of this analysis,
further prospective studies are still needed to not only explore
the utility and dynamicity of CRP in HFpEF but also to deter-
mine whether risk stratification algorithms incorporating CRP
actually provide a material benefit in bettering long-term out-
comes. All in all, obtaining a greater understanding of CRP in
the context of HFpEF through a consistent, repetitive demon-
stration of such findings in the in future prospective investi-
gations, new treatment strategies can be devised and patient
guidance can accordingly be enhanced to improve overall
prognosis.
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